Phase 3 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a formal consent form agreeing to participate in the study.
• People who are generally well enough to carry out daily activities with little to no limitation (rated 0 or 1 on a standard medical fitness scale).
• People who have been diagnosed with a specific type of cancer confirmed by laboratory testing — ovarian cancer, fallopian tube cancer, or primary peritoneal cancer — that started in the lining of these organs (called epithelial cancer).
• People who have already received a first course of platinum-based chemotherapy (given by drip or directly into the abdomen) after surgery, and whose cancer has since come back.
• People whose cancer returned within 12 months of finishing their last chemotherapy treatment (platinum-based or otherwise).
• People who have measurable tumours visible on scans at the start of the study, based on standard measurement guidelines.
• People with a life expectancy of at least 12 weeks.
• People who can provide a tumour tissue sample — either from a previous surgery or a newly collected sample taken during the screening period.
• People whose major organ systems (such as liver, kidneys, and bone marrow) are functioning at an adequate level.
• People who have not yet fully recovered from side effects of a previous treatment (confirm with trial site).

Who may not be able to join:

• People whose ovarian, peritoneal, or fallopian tube cancer is of certain specific types, including non-epithelial, borderline, mucinous, predominantly mucinous seromucinous, malignant Brenner's tumour, or undifferentiated carcinoma.
• People who have previously been treated with certain immune checkpoint therapies that target specific proteins on immune cells (such as PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137), or who have taken part in a previous study involving adebrelimab.
• People who have received any systemic cancer treatment, radiation therapy, or maintenance therapy within 4 weeks before joining the study.
• People who have had a severe allergic reaction (Grade 3 or higher) or have uncontrolled high blood pressure related to any of the study drugs or their ingredients.
• People who have had major surgery within 3 weeks before joining the study, or who are still recovering from complications of surgery.
• People who have had another type of cancer in the last 5 years that was growing or required active treatment.
• People who are pregnant or currently breastfeeding.
• People who have received a transplant of tissue or a solid organ from another person.
• People who have a history of blood clotting disorders, significant bleeding, coughing up blood, or active gastrointestinal bleeding within the past 6 months.
• People with a history of active autoimmune disease (a condition where the immune system attacks the body's own tissues).
• People who currently have an active infection that requires treatment throughout the body (such as intravenous or oral antibiotics or antivirals).
• People who have a history of HIV infection.
• People who have a history of Hepatitis B or Hepatitis C infection.
• People with any other medical condition, history, or circumstance that the trial team determines could interfere with the study results (confirm with trial site).
• People with a known mental health condition or substance use disorder that could make it difficult to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.